Archive | September, 2017

Drug Patent Expirations for Sep 28, 2017

DrugPatentWatch is your source business intelligence on small-molecule drugs and the 100,000 global patents covering them Click the patents below for more details, or visit DrugPatentWatch.com for more options. OCTREOSCAN (indium in-111 pentetreotide kit) Mallinkrodt Nuclear Patent number: 6,123,916 Expiration Date: Sep 26, 2017 SYMBICORT (budesonide; formoterol fumarate dihydrate) Astrazeneca Patent number: 6,123,924 Expiration Date: […]

Continue Reading

Heparin promotes food intake and body weight gain in animal models

In continuation of my update on Heparin…..………………………………… Heparin is a medication widely used to prevent blood clotting; it is named after and mimics the naturally occurring anticoagulant in the body. However, research published today in Cell Reports shows a novel role of heparin as a promoter of food intake and body weight increase in animal models. These […]

Continue Reading

Mild pain killer blocks action of key protein required for hearing

In continuation of my update on ‘diflunisal‘ A Rice University study has found that the aspirin-like drug diflunisal blocks the action of prestin, a key protein that is required for hearing. The research, which is available online in the open-access journal PLOS ONE, stemmed from a 2015 Rice study that screened more than a half-dozen nonsteroidal […]

Continue Reading

Cancer drug may inhibit growth of cysts in patients with inherited form of kidney disease

In continuation of my update on bostinib A cancer drug called bosutinib may inhibit the growth of cysts in patients with autosomal dominant polycystic kidney disease (ADPKD), according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings point to a potential new treatment strategy for affected […]

Continue Reading

New drug shows promising results for treating spinal muscular atrophy

A drug developed by an Iowa State University biomedical researcher as a potential treatment for spinal muscular atrophy showed promising results in a recently published study. Ravindra Singh, a professor of biomedical sciences in the ISU College of Veterinary Medicine, has been studying spinal muscular atrophy, a leading genetic cause of infant mortality, for years. […]

Continue Reading

Combo immunotherapy may herald new standard of care for kidney cancer

Combination therapy with two immunotherapy drugs produces an unprecedented doubling of response rates from 20 percent to 40 percent, a new study shows. The multicenter trial involving 100 patients showed that the addition of ipilimumab to nivolumab, which is currently FDA-approved for treatment of kidney cancer, leads to responses that can last beyond two years. Half […]

Continue Reading

Sorafenib effect on HCC survival depends on hepatitis status

For patients with advanced unresectable hepatocellular carcinoma, the effect of sorafenib on overall survival (OS) is dependent on patients’ hepatitis. Richard Jackson, from the Liverpool Cancer Trials Unit in the United Kingdom, and colleagues undertook an individual patient data meta-analysis of three prospective randomized trials in which sorafenib was the control arm. Data were included […]

Continue Reading

Drug Patent Expirations for Sep 14, 2017

DrugPatentWatch is your source business intelligence on small-molecule drugs and the 100,000 global patents covering them Click the patents below for more details, or visit DrugPatentWatch.com for more options. ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION (fexofenadine hydrochloride; pseudoephedrine hydrochloride) Sanofi Aventis Us Patent number: 6,037,353 Expiration Date: Sep 14, 2017 ALLEGRA (fexofenadine hydrochloride) Sanofi Aventis […]

Continue Reading